Editorial Board — Medscape Oncology

Board Members

  • Harold J. Burstein, MD, PhD
    • Harvard Medical School
      Dana-Farber Cancer Institute
      Boston, Massachusetts
  • Bruce D. Cheson, MD
    • Georgetown University
      Georgetown University Hospital
      Washington, DC
  • David J. Kerr, MD
    • University of Oxford
      Oxford Cancer Centre
      Oxford, United Kingdom
  • Mark G. Kris, MD
    • Memorial Sloan-Kettering Cancer Center
      Weill Cornell Medical College
      New York, New York
  • Corey J. Langer, MD
    • University of Pennsylvania Medical School
      Abramson Cancer Center
      Philadelphia, Pennsylvania
  • Maurie Markman, MD
    • Drexel University College of Medicine
      Cancer Treatment Centers of America
      Philadelphia, Pennsylvania
  • John L. Marshall, MD
    • Georgetown University
      Washington, DC
  • Kathy D. Miller, MD
    • Indiana University School of Medicine
      Indiana University Simon Cancer Center
      Indianapolis, Indiana
  • Richard M. Stone, MD
    • Harvard Medical School
      Dana-Farber Cancer Institute
      Boston, Massachusetts
  • Nicholas J. Vogelzang, MD
    • University of Nevada School of Medicine
      Comprehensive Cancer Centers of Nevada
      Las Vegas, Nevada
  • Louis M. Weiner, MD
    • Georgetown University Medical Center
      Lombardi Comprehensive Cancer Center
      Washington, DC
  • John R. Wingard, MD
    • University of Florida
      Shands Cancer Hospital at the University of Florida
      Gainesville, Florida
 

Board Member Details

Harold J. Burstein, MD, PhD
Harold J. Burstein, MD, PhD

Professor, Department of Medicine, Harvard Medical School. Boston, Massachusetts

Harold J. Burstein, MD, PhD, has disclosed no relevant financial relationships.

Bruce D. Cheson, MD
Bruce D. Cheson, MD

Professor of Medicine, Department of Hematology-Oncology; Deputy Chief, Hematology-Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC

Bruce D. Cheson, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; AstraZeneca; TG Therapeutics; Celgene; Roche-Genentech; Epizyme; Gilead; Seattle Genetics; Morphosys; Bayer; Karyopharm
Received research grant from: AbbVie; AstraZeneca; TG Therapeutics; Celgene; Roche-Genentech; Epizyme; Gilead; Seattle Genetics; Trillium

David J. Kerr, CBE, MD, DSc, FRCP, FMedSci
David J. Kerr, MD

Professor, Nuffield Department of Clinical Laboratory Science, University of Oxford; Professor of Cancer Medicine, Oxford Cancer Centre, Oxford, United Kingdom

David Kerr, CBE, MD, DSc, FRCP, FMedSci, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Celleron Therapeutics; Oxford Cancer Biomarkers; Cancer Care Commission; IQVEA
Received research grant from: Bayer
Have a 5% or greater equity interest in: Celleron Therapeutics; Oxford Cancer Biomarkers; Cancer Care Commission
Received income in an amount equal to or greater than $250 from: Celleron Therapeutics; Oxford Cancer Biomarkers; IQVEA

Mark G. Kris, MD
Mark G. Kris, MD

Professor of Medicine, Weill Cornell Medical College; Attending Physician, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

Mark G. Kris, MD, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: AstraZeneca; Pfizer; Regeneron
Received honoraria for participating education programs from: WebMD; OncLive; Physicians Education Resource; Prime Oncology; Intellisphere; Creative Educational Concepts; Peerview; i3 Health; Paradigm Medical Communications; AXIS; Carvive Systems; AstraZeneca; Research to Practice
Memorial Sloan Kettering Cancer Center has received funding for research conducted by Dr Kris from: The National Cancer Institute (USA); The Lung Cancer Research Foundation; Genentech Roche; PUMA Biotechnology
Memorial Sloan Kettering Cancer Center has an institutional agreement with IBM for Watson For Oncology and receives royalties from IBM
Funds for business meals, travel, and accommodations have been provided by AstraZeneca and Genentech

Corey J. Langer, MD
Corey J. Langer, MD

Professor of Medicine, University of Pennsylvania Medical School; Director, Thoracic Oncology, Abramson Cancer Center, Philadelphia, Pennsylvania

Corey J. Langer, MD, has disclosed the following relevant financial relationships:
Received institutional grant/research support from: Pfizer; Eli Lilly; Genentech; OSI (Astellas); Merck; GlaxoSmithKline; Nektar; Advantage; Clovis; Inovio; Ariad; StemCentrx; Takeda
Served as a scientific advisor for: AbbVie; Bristol Myers Squibb; ImClone; Pfizer; Eli Lilly; AstraZeneca; Novartis; Roche/Genentech; Bayer/Onyx; Abbott; Morphotek; Biodesix; Clarient; Caris Dx; Vertex; Synta; Celgene; Boehringer-Ingelheim; Hospira; Helsinn; Clovis; Ariad (Takeda); Takai; Regeneron
Data Safety Monitoring Committee Member: Eli Lilly; Amgen; Synta; Agennix; SWOG; Peregrine; Incyte
CME: Projects in Knowledge; Physicians' Education Resource; Network of Oncology Clinicians and Researchers; Imedex; Clinical Care Options; Research to Practice; Med Learning Group; TRM Oncology; WebMD

Maurie Markman, MD
Maurie Markman, MD

Clinical Professor of Medicine, Drexel University College of Medicine; President, Medicine & Science, Cancer Treatment Centers of America, Philadelphia, Pennsylvania

Maurie Markman, MD, has disclosed the following relevant financial relationships:
Serve(d) as a speaker or a member of a speakers bureau for: Genentech, Inc; Clovis; Tesaro; AstraZeneca Pharmaceuticals, LP
Received income in an amount equal to or greater than $250 from: Merck & Co., Inc.; Nanology; Delmar Pharmaceuticals; Celgene Corporation

John L. Marshall, MD
John L. Marshall, MD

Professor, Chief, Division of Hematology-Oncology, Department of Oncology, Georgetown University; Director, Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown University Hospital, Washington, DC

John L. Marshall, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Genentech; Amgen; Taiho; Bayer; Celgene; Ipsen; Caris; Merck
Serve(d) as a speaker or a member of a speakers bureau for: Genentech; Amgen; Taiho; Bayer; Celgene; Ipsen; Caris; Merck
Received research grant from: Genentech; Amgen; Taiho; Bayer; Celgene; Ipsen; Caris; Merck

Kathy D. Miller, MD
Kathy D. Miller, MD

Professor, Department of Hematology/Oncology; Associate Director, Indiana University School of Medicine, Indianapolis, Indiana

Kathy D. Miller, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Merck & Nektar Breast CA trials (Data and Safety Monitoring Committee)

Richard M. Stone, MD
Richard M. Stone, MD

Professor of Medicine, Harvard Medical School; Director, Translational Research Division, Dana-Farber Cancer Institute, Boston, Massachusetts

Richard M. Stone, MD, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: AbbVie; Actinium; Agios; Amgen Inc.; Arog; Astellas; AstraZeneca; Celgene; Cornerstone; Jazz; Macrogenics; Novartis; Otsuka/Astex; Pfizer; Stemline
Received research funding from: Agios; Arog; Novartis
Serve(d) on the Data Safety and Monitoring Board for: Celgene; Argenx; Takeda
Serve(d) on the Steering Committee for: Celgene

Nicholas J. Vogelzang, MD
Nicholas J. Vogelzang, MD

Professor of Clinical Medicine, University of Nevada School of Medicine, University of Nevada, Las Vegas, Nevada

Nicholas J. Vogelzang, MD, has disclosed no relevant financial relationships.

Louis M. Weiner, MD
Louis M. Weiner, MD

Chairman, Francis L. and Charlotte G. Gragnani Chair and Professor, Department of Oncology, Georgetown University Medical Center; Director, Lombardi Comprehensive Cancer Center; Director, MedStar Georgetown Cancer Institute, Georgetown University Medical Center, Washington, DC

Louis M. Weiner, MD, has disclosed the following relevant financial relationships:
Serve(d) on the Scientific Advisory Board for: Celldex; Jounce Therapeutics; Immunome; Klus Pharmaceuticals; Forty-Seven, Inc.
Serve(d) on the External Advisory Board for: Cytomx
Serve(d) on the Clinical Advisory Board for: Bioxcel
Serve(d) as a consultant for: Novartis
Is the co-founder of: Jounce Therapeutics
Has investment in: Targeted Diagnostic and Therapeutics, Inc.

John R. Wingard, MD
John R. Wingard, MD

Professor, Department of Medicine, University of Florida; Director, Bone Marrow Transplant Program, Shands Hospital at University of Florida, Gainesville, Florida

John R. Wingard, MD, has disclosed the following relevant financial relationships:
Serve(d) on the board of directors for: National Marrow Transplant Program (Emeritus)
Received income in an amount equal to or greater than $250 from: Shire; Celgene; Astellas; Pluristem; Merck